Psyence Biomedical (PBM) Common Equity (2024 - 2025)

Psyence Biomedical (PBM) recorded quarterly Common Equity of $11.9 million in Q3 2025, up 76.54% quarter-over-quarter from $6.7 million in Q1 2025.

Psyence Biomedical (PBM) Common Equity (2024 - 2025) Analysis & Trends

Psyence Biomedical's Common Equity history runs 2 years deep, the most recent figure standing at $11.9 million for Q3 2025.

In Q3 2025, Common Equity changed N/A year-over-year to $11.9 million; the TTM figure through Sep 2025 stood at $11.9 million (changed N/A YoY), while the FY2025 annual figure was $6.7 million, up 161.26% from the prior year.
Common Equity was $11.9 million for Q3 2025 at Psyence Biomedical, up from $6.7 million in the prior quarter.
In the past five years, Common Equity ranged from a high of $11.9 million in Q3 2025 to a low of -$11.0 million in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Common Equity (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	35.63 Mn
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-1.42 Mn
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	13.21 Mn
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	14.38 Mn
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	11.87 Mn
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	19.36 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Regeneron Pharmaceuticals	63.43 Bn	54.67 Bn	3.31 Bn	31.42 Bn

Download Data